Dendritic cell vaccination as a treatment modality for melanoma

Expert Review of Anticancer Therapy

Volumn 9, Issue 11, 2009, Pages 1631-1642

  Eubel, Jana ^a   Enk, Alexander H ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cancer immunotherapy; Cancer vaccination; Dendritic cell; Melanoma

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ALPHA2B INTERFERON; BCG VACCINE; COMPLEMENTARY DNA; CPG OLIGODEOXYNUCLEOTIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; DENDRITIC CELL VACCINE; DENILEUKIN DIFTITOX; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN; IMIQUIMOD; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; IPILIMUMAB; MAJOR HISTOCOMPATIBILITY ANTIGEN; MELAN A; MELANOMA ANTIGEN 1; MELANOMA ANTIGEN 3; MELANOMA VACCINE; MESSENGER RNA; PEPTIDE VACCINE; TOLL LIKE RECEPTOR AGONIST; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE; UNINDEXED DRUG;

ADJUVANT THERAPY; ANOREXIA; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTHRALGIA; AUTOIMMUNE DISEASE; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG FEVER; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; FLU LIKE SYNDROME; HIGH RISK PATIENT; HUMAN; HYPOTENSION; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; INFECTION; INJECTION SITE REACTION; LETHARGY; LOW DRUG DOSE; LYMPH NODE METASTASIS; MALAISE; MELANOMA; MYALGIA; NONHUMAN; OVERALL SURVIVAL; PROGNOSIS; REVIEW; SINGLE DRUG DOSE; SKIN SURGERY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; VITILIGO;

CANCER VACCINES; COMBINED MODALITY THERAPY; DENDRITIC CELLS; HUMANS; MELANOMA; SKIN NEOPLASMS; VACCINATION;

EID: 71949123992     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.139     Document Type: Review

References (124)

1. Hall HI, Miller DR, Rogers JD, Bewerse B. Update on the incidence and mortality from melanoma in the United States. J. Am. Acad. Dermatol. 40(1), 35-42 (1999). (Pubitemid 29051022)
2. Purdue MP, Freeman LE, Anderson WF, Tucker MA. Recent trends in incidence of cutaneous melanoma among US Caucasian young adults. J. Invest. Dermatol. 128(12), 2905-2908 (2008).
3. Cokkinides V, Weinstock M, Glanz K, Albano J, Ward E, Thun M. Trends in sunburns, sun protection practices, and attitudes toward sun exposure protection and tanning among US adolescents, 1998-2004. Pediatrics 118(3), 853-864 (2006).
4. Lazovich D, Forster J. Indoor tanning by adolescents: prevalence, practices and policies. Eur. J. Cancer 41(1), 20-27 (2005). (Pubitemid 40029656)
5. International Agency for Research on Cancer Working Group on artificial ultraviolet (UV) light and skin cancer. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: a systematic review. Int. J. Cancer 120(5), 1116-1122 (2007).
6. Cote TR, Sobin LH. Primary melanomas of the esophagus and anorectum: epidemiologic comparison with melanoma of the skin. Melanoma Res. 19(1), 58-60 (2009).
7. Jasser SA, Blask DE, Brainard GC. Light during darkness and cancer: relationships in circadian photoreception and tumor biology. Cancer Causes Control 17(4), 515-523 (2006).
8. Garbe C, Buttner P, Bertz J et al. Primary cutaneous melanoma. Identification of prognostic groups and estimation of individual prognosis for 5093 patients. Cancer 75(10), 2484-2491 (1995).
9. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol. 4(12), 748-759 (2003). (Pubitemid 37527210)
10. Balch CM, Soong SJ, Gershenwald JE et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 19(16), 3622-3634 (2001).
11. Kim CJ, Dessureault S, Gabrilovich D, Reintgen DS, Slingluff CL Jr. Immunotherapy for melanoma. Cancer Control 9(1), 22-30 (2002).
12. Nathanson. Spontaneous regression of malignant melanoma: a review of the literature on incidence, clinical features, and possible mechanisms. Natl Cancer Inst. Monogr. 44, 67-76 (1976).
13. Eggermont AM, Schadendorf D. Melanoma and immunotherapy. Hematol. Oncol. Clin. North Am. 23(3), 547-564, ix-x (2009).
14. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-α for high-risk melanoma provide a worthwhile benefit? A metaanalysis of the randomised trials. Cancer Treat. Rev. 29(4), 241-252 (2003). (Pubitemid 37069655)
15. Ascierto PA, Kirkwood JM. Adjuvant therapy of melanoma with interferon: lessons of the past decade. J. Transl. Med. 6, 62 (2008).
16. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon α-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J. Clin. Oncol. 14(1), 7-17 (1996).
17. Kirkwood JM, Ibrahim JG, Sondak VK et al. High- and low-dose interferon α-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J. Clin. Oncol. 18(12), 2444-2458 (2000).
18. Kirkwood JM, Ibrahim JG, Sosman JA et al. High-dose interferon α-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J. Clin. Oncol. 19(9), 2370-2380 (2001).
19. Kirkwood JM, Bender C, Agarwala S et al. Mechanisms and management of toxicities associated with high-dose interferon α-2b therapy. J. Clin. Oncol. 20(17), 3703-3718 (2002). (Pubitemid 34983231)
20. Wheatley K, Ives N, Eggermont A et al. Interferon-α as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials. Proc. Am. Soc. Clin. Oncol. 25, 478S (2007).
21. Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17(7), 2105-2116 (1999).
22. Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271(12), 907-913 (1994).
23. Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM. Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N. Engl. J. Med. 318(24), 1557-1563 (1988).
24. Bouwhuis MG, Suciu S, Collette S et al. Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon. J. Natl Cancer Inst. 101(12), 869-877 (2009).
25. Agarwala SS, Neuberg D, Park Y, Kirkwood JM. Mature results of a Phase III randomized trial of bacillus Calmette- Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer 100(8), 1692-1698 (2004). (Pubitemid 38456347)
26. Green DS, Bodman-Smith MD, Dalgleish AG, Fischer MD. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br. J. Dermatol. 156(2), 337-345 (2007).
27. Green DS, Dalgleish AG, Belonwu N, Fischer MD, Bodman-Smith MD. Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma. Br. J. Dermatol. 159(3), 606-614 (2008).
28. Camacho LH, Antonia S, Sosman J et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J. Clin. Oncol. 27(7), 1075-1081 (2009).
29. Weber JS, O'Day S, Urba W et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J. Clin. Oncol. 26(36), 5950-5956 (2008).
30. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 449(7161), 419-426 (2007). • Review on the use of dendritic cells (DCs) in medicine.
31. Ebner S, Ehammer Z, Holzmann S et al. Expression of C-type lectin receptors by subsets of dendritic cells in human skin. Int. Immunol. 16(6), 877-887 (2004). (Pubitemid 38786528)
32. Nijman HW, Kleijmeer MJ, Ossevoort MA et al. Antigen capture and major histocompatibility class II compartments of freshly isolated and cultured human blood dendritic cells. J. Exp. Med. 182(1), 163-174 (1995).
33. Pierre P, Turley SJ, Gatti E et al. Developmental regulation of MHC class II transport in mouse dendritic cells. Nature 388(6644), 787-792 (1997). (Pubitemid 27375159)
34. Ackerman AL, Kyritsis C, Tampe R, Cresswell P. Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens. Proc. Natl Acad. Sci. USA 100(22), 12889-12894 (2003). (Pubitemid 37339995)
35. Fonteneau JF, Larsson M, Bhardwaj N. Interactions between dead cells and dendritic cells in the induction of antiviral CTL responses. Curr. Opin. Immunol. 14(4), 471-477 (2002). (Pubitemid 34671250)
36. Guermonprez P, Saveanu L, Kleijmeer M, Davoust J, Van Endert P, Amigorena S. ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. Nature 425(6956), 397-402 (2003). (Pubitemid 37187268)
37. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 124(4), 783-801 (2006).
38. Matzinger P. The danger model: a renewed sense of self. Science 296(5566), 301-305 (2002). (Pubitemid 34303674)
39. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5(10), 987-995 (2004). (Pubitemid 41057715)
40. Lechmann M, Berchtold S, Hauber J, Steinkasserer A. CD83 on dendritic cells: more than just a marker for maturation. Trends Immunol. 23(6), 273-275 (2002). (Pubitemid 34628763)
41. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J. Exp. Med. 182(2), 389-400 (1995).
42. Lanzavecchia A. Immunology. Licence to kill. Nature 393(6684), 413-414 (1998).
43. Fernandez NC, Lozier A, Flament C et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat. Med. 5(4), 405-411 (1999). (Pubitemid 29180578)
44. + T cell priming by dendritic cells in intact lymph nodes. Nat. Immunol. 4(6), 579-585 (2003).
45. Steinbrink K, Mahnke K, Grabbe S, Enk AH, Jonuleit H. Myeloid dendritic cell: from sentinel of immunity to key player of peripheral tolerance? Hum. Immunol. 70(5), 289-293 (2009).
46. Inaba K, Pack M, Inaba M, Sakuta H, Isdell F, Steinman RM. High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes. J. Exp. Med. 186(5), 665-672 (1997). (Pubitemid 27381531)
47. Schuler-Thurner B, Schultz ES, Berger TG et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med. 195(10), 1279-1288 (2002). (Pubitemid 34564330)
48. +) progenitor-derived dendritic cell vaccine. Cancer Res. 61(17), 6451-6458 (2001).
49. + T cells. J. Exp. Med. 198(4), 569-580 (2003).
50. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4(3), 328-332 (1998). • First study on DC-based vaccination in stage IV melanoma patients. (Pubitemid 28144092)
51. Thurner B, Haendle I, Roder C et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190(11), 1669-1678 (1999). (Pubitemid 30002348)
52. Wiedemann A, Depoil D, Faroudi M, Valitutti S. Cytotoxic T lymphocytes kill multiple targets simultaneously via spatiotemporal uncoupling of lytic and stimulatory synapses. Proc. Natl Acad. Sci. USA 103(29), 10985-10990 (2006). (Pubitemid 44148405)
53. Shankaran V, Ikeda H, Bruce AT et al. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410(6832), 1107-1111 (2001). (Pubitemid 32391043)
54. Chiao EY, Krown SE. Update on non-acquired immunodeficiency syndrome-defining malignancies. Curr. Opin. Oncol. 15(5), 389-397 (2003).
55. Jonuleit H, Giesecke-Tuettenberg A, Tuting T et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int. J. Cancer 93(2), 243-251 (2001). (Pubitemid 32574281)
56. Schadendorf D, Ugurel S, Schuler-Thurner B et al. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized Phase III trial of the DC study group of the DeCOG. Ann. Oncol. 17(4), 563-570 (2006). • The largest Phase III clinical trial comparing DC-based vaccination with standard dacarbazine chemotherapy in stage IV melanoma patients.
57. Luongo V, Pirozzi G, Caraco C et al. HLA allele frequency and clinical outcome in Italian patients with cutaneous melanoma. Tissue Antigens 64(1), 84-87 (2004). (Pubitemid 38850374)
58. Sosman JA, Unger JM, Liu PY et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J. Clin. Oncol. 20(8), 2067-2075 (2002).
59. +) T cell immunity. Nat. Immunol. 5(11), 1143-1148 (2004).
60. Slingluff CL Jr, Petroni GR, Yamshchikov GV et al. Clinical and immunologic results of a randomized Phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J. Clin. Oncol. 21(21), 4016-4026 (2003).
61. Tuettenberg A, Becker C, Huter E, Knop J, Enk AH, Jonuleit H. Induction of strong and persistent MelanA/MART-1-specific immune responses by adjuvant dendritic cell-based vaccination of stage II melanoma patients. Int. J. Cancer 118(10), 2617-2627 (2006). • DC-based vaccination study performed in stage II melanoma patients.
62. Fontana R, Bregni M, Cipponi A et al. Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce anti-tumor immune responses in cancer patients. Blood 113(8), 1651-1660 (2009).
63. de Vries IJ, Lesterhuis WJ, Scharenborg NM et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin. Cancer Res. 9(14), 5091-5100 (2003).
64. + progenitors in human bone marrow. J. Immunol. 149(8), 2681-2688 (1992).
65. + hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF + TNF α. J. Exp. Med. 184(2), 695-706 (1996).
66. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colonystimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med. 179(4), 1109-1118 (1994). (Pubitemid 24091769)
67. Rossi G, Heveker N, Thiele B, Gelderblom H, Steinbach F. Development of a Langerhans cell phenotype from peripheral blood monocytes. Immunol. Lett. 31(2), 189-197 (1992).
68. Dauer M, Obermaier B, Herten J et al. Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J. Immunol. 170(8), 4069-4076 (2003). (Pubitemid 36428169)
69. Jonuleit H, Kuhn U, Muller G et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27(12), 3135-3142 (1997). (Pubitemid 28018007)
70. + T cell populations lacking helper function. Nat. Immunol. 6(2), 163-170 (2005).
71. Mailliard RB, Wankowicz-Kalinska A, Cai Q et al. α-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 64(17), 5934-5937 (2004). (Pubitemid 39129387)
72. Trepiakas R, Pedersen AE, Met O, Hansen MH, Berntsen A, Svane IM. Comparison of α-type-1 polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocytederived dendritic cell preparations from cancer patients. Vaccine 26(23), 2824-2832 (2008).
73. O'Rourke MG, Johnson M, Lanagan C et al. Durable complete clinical responses in a Phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol. Immunother. 52(6), 387-395 (2003). (Pubitemid 36693759)
74. Dillman RO, Selvan SR, Schiltz PM et al. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific anti-tumor vaccines in patients with metastatic melanoma: final report. Cancer Biother. Radiopharm. 24(3), 311-319 (2009).
75. von Euw EM, Barrio MM, Furman D et al. A Phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 1082 promoter genotype as predictor of disease progression. J. Transl. Med. 6, 6 (2008).
76. Hersey P, Halliday GM, Farrelly ML, DeSilva C, Lett M, Menzies SW. Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma. Cancer Immunol. Immunother. 57(7), 1039-1051 (2008). (Pubitemid 351601491)
77. Redman BG, Chang AE, Whitfield J et al. Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma. J. Immunother. 31(6), 591-598 (2008).
78. + T cell responses to infectious agents, tumors, transplants, and vaccines. Adv. Immunol. 73, 1-77 (1999).
79. Van Tendeloo VF, Ponsaerts P, Lardon F et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 98(1), 49-56 (2001).
80. Caruso DA, Orme LM, Neale AM et al. Results of a Phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro Oncol. 6(3), 236-246 (2004).
81. Su Z, Dannull J, Heiser A et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 63(9), 2127-2133 (2003). (Pubitemid 36538616)
82. Gilboa E, Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol. Rev. 199, 251-263 (2004). (Pubitemid 38744521)
83. Kyte JA, Mu L, Aamdal S et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther. 13(10), 905-918 (2006). (Pubitemid 44373791)
84. Wei Y, Sticca RP, Holmes LM et al. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. Int. J. Oncol. 28(3), 585-593 (2006).
85. Eggert AA, Schreurs MW, Boerman OC et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res. 59(14), 3340-3345 (1999).
86. Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, Lyerly HK. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res. 59(1), 56-58 (1999). (Pubitemid 29062955)
87. De Vries IJ, Krooshoop DJ, Scharenborg NM et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 63(1), 12-17 (2003).
88. Ridolfi R, Riccobon A, Galassi R et al. Evaluation of in vivo labelled dendritic cell migration in cancer patients. J. Transl. Med. 2(1), 27 (2004). (Pubitemid 40617863)
89. Barratt-Boyes SM, Watkins SC, Finn OJ. In vivo migration of dendritic cells differentiated in vitro: a chimpanzee model. J. Immunol. 158(10), 4543-4547 (1997).
90. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG. Dendritic cells injected via different routes induce immunity in cancer patients. J. Immunol. 166(6), 4254-4259 (2001). (Pubitemid 32224961)
91. Serody JS, Collins EJ, Tisch RM, Kuhns JJ, Frelinger JA. T cell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery. J. Immunol. 164(9), 4961-4967 (2000).
92. James K, Eisenhauer E, Christian M et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J. Natl Cancer Inst. 91(6), 523-528 (1999). (Pubitemid 29157060)
93. Engelhard VH, Bullock TN, Colella TA, Sheasley SL, Mullins DW. Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol. Rev. 188, 136-146 (2002).
94. Campoli MR, Chang CC, Kageshita T, Wang X, McCarthy JB, Ferrone S. Human high molecular weight-melanoma-associated antigen (HMW-MAA): a melanoma cell surface chondroitin sulfate proteoglycan (MSCP) with biological and clinical significance. Crit. Rev. Immunol. 24(4), 267-296 (2004). (Pubitemid 40052428)
95. Velculescu VE, Madden SL, Zhang L et al. Analysis of human transcriptomes. Nat. Genet. 23(4), 387-388 (1999).
96. Thomas J, Liu T, Cotter MA et al. Melanocyte expression of survivin promotes development and metastasis of UV-induced melanoma in HGF-transgenic mice. Cancer Res. 67(11), 5172-5178 (2007). (Pubitemid 46997254)
97. Mittelman A, Chen ZJ, Yang H, Wong GY, Ferrone S. Human high molecular weight melanoma-associated antigen (HMWMAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc. Natl Acad. Sci. USA 89(2), 466-470 (1992).
98. Li F, Ambrosini G, Chu EY et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396(6711), 580-584 (1998). (Pubitemid 28563719)
99. Vong QP, Cao K, Li HY, Iglesias PA, Zheng Y. Chromosome alignment and segregation regulated by ubiquitination of survivin. Science 310(5753), 1499-1504 (2005). (Pubitemid 41746347)
100. Otto K, Andersen MH, Eggert A et al. Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin. Vaccine 23(7), 884-889 (2005). (Pubitemid 39643175)
101. Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH, Becker JC. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol. Immunother. 55(10), 1294-1298 (2006). (Pubitemid 43992055)
102. +) T cells with regulatory properties isolated from peripheral blood. J. Exp. Med. 193(11), 1285-1294 (2001).
103. Liyanage UK, Moore TT, Joo HG et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169(5), 2756-2761 (2002).
104. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10(9), 942-949 (2004). (Pubitemid 39273735)
105. Enk AH, Jonuleit H, Saloga J, Knop J. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int. J. Cancer 73(3), 309-316 (1997). (Pubitemid 27508890)
106. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol. 159(10), 4772-4780 (1997). (Pubitemid 127471012)
107. Mahnke K, Schmitt E, Bonifaz L, Enk AH, Jonuleit H. Immature, but not inactive: the tolerogenic function of immature dendritic cells. Immunol. Cell. Biol. 80(5), 477-483 (2002).
108. Dannull J, Su Z, Rizzieri D et al. Enhancement of vaccine-mediated anti-tumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115(12), 3623-3633 (2005). • Enhancing effectiveness of DC-based cancer vaccines by depletion of Tregs. (Pubitemid 43121851)
109. + human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int. J. Cancer 120(12), 2723-2733 (2007). • Enhancing effectiveness of DC-based cancer vaccines by depletion of Tregs.
110. Attia P, Maker AV, Haworth LR, Rogers-Freezer L, Rosenberg SA. Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. J. Immunother. 28(6), 582-592 (2005). (Pubitemid 41533092)
111. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 5(6), 471-484 (2006). • Toll-like receptor 9 agonists as potential agents to be combined with DC-based vaccination.
112. Pashenkov M, Goess G, Wagner C et al. Phase II trial of a Toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J. Clin. Oncol. 24(36), 5716-5724 (2006). (Pubitemid 46631314)
113. West MA, Wallin RP, Matthews SP et al. Enhanced dendritic cell antigen capture via Toll-like receptor-induced actin remodeling. Science 305(5687), 1153-1157 (2004).
114. + T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. J. Clin. Invest. 115(3), 739-746 (2005).
115. Brunet JF, Denizot F, Luciani MF et al. A new member of the immunoglobulin superfamily - CTLA-4. Nature 328(6127), 267-270 (1987). (Pubitemid 17108278)
116. Korman AJ, Peggs KS, Allison JP. Checkpoint blockade in cancer immunotherapy. Adv. Immunol. 90, 297-339 (2006). • Anti-CTLA-4-antibodies as potential agents to be combined with DC-based vaccination.
117. Ribas A. Clinical trials with tumor antigen genetically modified dendritic cells. Semin. Oncol. 32(6), 556-562 (2005). (Pubitemid 41772683)
118. Ribas A, Camacho LH, Lopez-Berestein G et al. Antitumor activity in melanoma and anti-self responses in a Phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J. Clin. Oncol. 23(35), 8968-8977 (2005). (Pubitemid 46217464)
119. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182(2), 459-465 (1995).
120. Maker AV, Phan GQ, Attia P et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a Phase I/II study. Ann. Surg. Oncol. 12(12), 1005-1016 (2005). (Pubitemid 41660676)
121. Ribas A, Hanson DC, Noe DA et al. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist 12(7), 873-883 (2007). (Pubitemid 47328230)
122. Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene 27(45), 5904-5912 (2008).
123. American Cancer Society, Cancer Facts and Figures 2009 www.cancer.org/downloads/ STT/500809web.pdf
124. American Academy of Dermatology, Melanoma Fact Sheet www.aad.org/media/ background/ factsheets/fact-melanoma.html